DK2147014T3 - 17alfa-substituterede steroider som systemiske anti-androgener og selektive androgenreceptormodulatorer - Google Patents

17alfa-substituterede steroider som systemiske anti-androgener og selektive androgenreceptormodulatorer Download PDF

Info

Publication number
DK2147014T3
DK2147014T3 DK08748116.4T DK08748116T DK2147014T3 DK 2147014 T3 DK2147014 T3 DK 2147014T3 DK 08748116 T DK08748116 T DK 08748116T DK 2147014 T3 DK2147014 T3 DK 2147014T3
Authority
DK
Denmark
Prior art keywords
compound
mmol
pyr
group
inhibitor
Prior art date
Application number
DK08748116.4T
Other languages
English (en)
Inventor
Fernand Labrie
Sylvain Gauthier
Julie Cloutier
Josée Mailhot
Steeves Potvin
Sylvain Dion
Jean-Yves Sancéau
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Application granted granted Critical
Publication of DK2147014T3 publication Critical patent/DK2147014T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Forbindelse, et salt eller et N-oxidderivat deraf, som har den følgende molekylære formel:
hvor n er et heltal fra 1 til 2; hvor R2 er valgt fra gruppen bestående af hydrogen og fluor; hvor R3 er valgt fra gruppen bestående af hydrogen, cyano, chlor, methoxy, ethoxy, nitro, og propynyl; hvor R4 er valgt fra gruppen bestående af hydrogen, fluor, chlor, brom, cyano, amino, cyclopropyl og Ci-alkyl; hvor Rnp, er valgt fra gruppen bestående af hydrogen, fluor, Ci-C2-alkyl, og C2- alkenyl; hvor Ri7q og Ri73 er uafhængigt af hinanden valgt fra gruppen bestående af hydroxyl, methoxy og -A-A'-Ar A og A', som er en afstandsholdergruppe uafhængigt af hinanden valgt fra gruppen bestående af fraværende -CH2-, -CHF-, -CFI(CFl3)-, propynylen, og
(B og C, som er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, fluor, og methyl), og Ar, som er valgt fra gruppen bestående af:
(D, som er valgt fra gruppen bestående af hydrogen, fluor, chlor, brom, methyl, ethyl og methoxy og E, som er valgt fra gruppen bestående af hydrogen, cyano og methyl);
(f er CH eller nitrogen); og
(G, som er valgt fra gruppen bestående af cyano, -CONFER2 (R1 og R2 er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen og methyl) og -SOCH3; hvori når Ri7a er hydroxyl eller methoxy, Ri7p er -A-A'-Ar, og når Ri7p er hydroxyl eller methoxy, Ri7a er -A-A'-Ar.
2. Forbindelse, et salt eller et N-oxidderivat deraf, ifølge krav 1, der har den følgende molekylære formel:
hvor n er et heltal fra 1 til 2; hvor R4 er valgt fra gruppen bestående af fluor, chlor, og methyl; hvor Ri7a og Ri?3 er uafhængigt af hinanden valgt fra gruppen bestående af hydroxyl og -CH2-Ar Ar, som er valgt fra gruppen bestående af:
(D, som er valgt fra gruppen bestående af hydrogen, fluor, og methyl); hvori når Ri7a er hydroxyl, Ri7p er -CH2-Ar, og når Ri7p er hydroxyl, Ri7q er -CH2-Ar.
3. Forbindelse ifølge krav 1, der har en molekylær formel valgt fra gruppen bestående af:
4. Farmaceutisk sammensætning omfattende et farmaceutisk acceptabelt fortyndingsmiddel eller bærestof og en terapeutisk virkningsfuld mængde af mindst én forbindelse ifølge et hvilket som helst af krav 1-3.
5. Farmaceutisk sammensætning ifølge krav 4 yderligere omfattende en inhibitor af 5a-reduktase og en inhibitor af type 13 17p-hydroxysteroid-dehydrogenase.
6. Forbindelse ifølge et hvilket som helst af krav 1-3 til anvendelse i behandling af eller reducering af risikoen for at udvikle prostatacancer, til behandling af eller reducering af risikoen for at udvikle godartet prostatahyperplasi, til behandling af eller reducering af risikoen for at udvikle polycystisk ovariesyndrom, til behandling af eller reduceringen af risikoen for at udvikle akne, seborrhea, hirsutisme eller androgen alopeci, til behandling af for tidligt indtrædende pubertet, til behandling af eller reducering af risikoen for at udvikle sygdomme relateret til tab af androgen stimulation og/eller til behandling af eller reducering af risikoen for at udvikle muskelatrofi og svaghed, hudatrofi, muskeltab, anæmi, arte-riosklerose, cardiovaskulær sygdom, type 2 diabetes, akkumulering af abdominalt fedt.
7. Forbindelse til anvendelse ifølge krav 6 til behandling af eller reducering af risikoen for at udvikle prostata-cancer yderligere omfattende at indgive til patienterne, en terapeutisk virkningsfuld mængde af mindst én inhibitor valgt fra gruppen bestående af en inhibitor af type 13 173-hydroxysteroid-dehydrogenase, en inhibitor af type 5 17β-hydroxysteroid-dehydrogenase, en inhibitor af 5a-reduktase inhibitor eller en inhibitor af androgen-syntetiserende enzymer.
8. Forbindelse til anvendelse ifølge krav 6 til behandling af eller reducering af risikoen for at udvikle prostata-cancer yderligere omfattende at indgive en LHRH-agonist eller antagonist.
9. Forbindelse til anvendelse ifølge krav 6 til behandling af eller reducering af risikoen for at udvikle godartet prostatahyperplasi, yderligere omfattende at indgive til patienterne, en terapeutisk virkningsfuld mængde af mindst én inhibitor valgt fra gruppen bestående af et antiøstrogen, en inhibitor af aromatase, en inhibitor af type 13 17β-hydroxysteroid-dehydrogenase, og en inhibitor af 5a-reduktase.
10. Forbindelse til anvendelse ifølge krav 6 til behandling af eller reducering af risikoen for at udvikle polycystisk ovariesyndrom, yderligere omfattende at indgive til patienterne, en terapeutisk virkningsfuld mængde af mindst én inhibitor valgt fra gruppen bestående af en inhibitor af type 13 17β-hydroxysteroid-dehydrogenase, og en inhibitor af 5a-reduktase.
11. Forbindelse til anvendelse ifølge krav 6 til behandling af eller reducering af risikoen for at udvikle akne, seborrhea, hirsutisme eller androgen alopeci, yderligere omfattende at indgive til patienterne, en terapeutisk virkningsfuld mængde af mindst én inhibitor valgt fra gruppen bestående af en inhibitor af type 13 17β-hydroxysteroid-dehydrogenase, og en inhibitor af 5a-reduktase.
12. Forbindelse til anvendelse ifølge krav 6 til behandling af fortidligt indtrædende pubertet yderligere omfattende indgivelse til en mandlig patient, en terapeutisk virkningsfuld mængde af en LFIRFI-agonist eller antagonist.
13. Forbindelse til anvendelse ifølge krav 6 til behandling af fortidligt indtrædende pubertet yderligere omfattende indgivelse til en mandlig eller kvindelig patient, en terapeutisk virkningsfuld mængde afen type 13 17β-hydroxysteroid-dehydrogenaseinhibitor.
14. Forbindelse til anvendelse ifølge krav 6 til behandling af fortidligt indtrædende pubertet yderligere omfattende indgivelse til en mandlig patient, en terapeutisk virkningsfuld mængde af en type 13 17β-hydroxysteroid-dehydrogenaseinhibitor og en LHRH- agonist eller antagonist.
15. Forbindelse til anvendelse ifølge krav 12-14, yderligere omfattende indgivelse af en 5a-reduktaseinhibitor.
DK08748116.4T 2007-04-12 2008-04-11 17alfa-substituterede steroider som systemiske anti-androgener og selektive androgenreceptormodulatorer DK2147014T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91143407P 2007-04-12 2007-04-12
US91145207P 2007-04-12 2007-04-12
US12/100,372 US9284345B2 (en) 2007-04-12 2008-04-09 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
PCT/CA2008/000672 WO2008124922A1 (en) 2007-04-12 2008-04-11 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
DK2147014T3 true DK2147014T3 (da) 2016-05-17

Family

ID=39863194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08748116.4T DK2147014T3 (da) 2007-04-12 2008-04-11 17alfa-substituterede steroider som systemiske anti-androgener og selektive androgenreceptormodulatorer

Country Status (8)

Country Link
US (1) US9284345B2 (da)
EP (1) EP2147014B1 (da)
AU (1) AU2008238559B2 (da)
CA (1) CA2683522C (da)
DK (1) DK2147014T3 (da)
HU (1) HUE027508T2 (da)
NZ (1) NZ580328A (da)
WO (1) WO2008124922A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930181A (zh) 2004-01-07 2007-03-14 恩多研究公司 螺旋12定向的甾族药品
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2012143395A1 (en) 2011-04-20 2012-10-26 Syngenta Participations Ag 4,5-dihydro-isoxazole derivatives as fungicides
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RU2689988C2 (ru) * 2015-04-21 2019-05-30 Джи Ти Икс, ИНК. Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA2983426C (en) 2015-04-21 2023-10-17 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN106946963B (zh) * 2017-04-01 2019-09-20 湖南玉新药业有限公司 制备倍他米松的16β-甲基关键中间体的方法
CN106986907B (zh) * 2017-04-01 2019-09-20 湖南玉新药业有限公司 用于制备倍他米松的中间体的制备方法
SG11201911776PA (en) 2017-06-08 2020-01-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
US12337004B2 (en) 2019-04-27 2025-06-24 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer
WO2020263989A1 (en) 2019-06-24 2020-12-30 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
EP4353728A4 (en) * 2021-06-11 2025-07-16 Tokuyama Corp HYDROXYTHIENOIMIDAZOLE DERIVATIVE, VINYL SULFIDE DERIVATIVE, N-BUTYLIDENE SULFIDE DERIVATIVE AND PROCESS FOR PRODUCING A STRAIGHT-CHAIN SATURATED HYDROCARBON-SUBSTITUTED THIENOIMIDAZOLE
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
CN117534720A (zh) * 2022-08-01 2024-02-09 香港中文大学(深圳) 环戊烷多氢菲衍生物及其制备方法和应用
CN117720606A (zh) * 2023-12-21 2024-03-19 湖北竹溪人福药业有限责任公司 一种睾酮母液物循环回收利用的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2938030A (en) * 1956-10-03 1960-05-24 Ciba Pharm Prod Inc New steroids substituted by a heterocyclic nitrogen-containing ring in 17-position
DE1107664B (de) * 1959-11-05 1961-05-31 Schering Ag Verfahren zur Herstellung neuer in 3-Stellung substituierter OEstratriene
FR1473910A (fr) 1965-11-16 1967-03-24 Lilly Co Eli Procédé de préparation d'un nouvel ester de 3-méthoxyoestradiol
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
HU208150B (en) 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
CA2062973C (en) 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE4338316A1 (de) * 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
AU717251B2 (en) 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US7759520B2 (en) * 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
AU7604798A (en) 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
MXPA00008868A (es) 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
JP2002522380A (ja) 1998-08-07 2002-07-23 アンドルシェルシュ・インコーポレイテッド タイプ33α−ヒドロキシステロイドデヒドロゲナーゼの阻害
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001098322A1 (en) 2000-06-22 2001-12-27 Northeastern University Novel steroidal antiestrogens and antiandrogens and uses thereof
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
JP2002088073A (ja) 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
IL155019A0 (en) 2000-09-19 2003-10-31 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
JP4898446B2 (ja) 2003-06-13 2012-03-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的なアンドロゲン受容体モジュレーター(sarms)としてのチアゾリン誘導体
SE0301934L (sv) 2003-06-30 2005-02-22 Delaval Holding Ab Mjölkningsanordning och förfarande för hantering av en mjölkningsanordning
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005048956A2 (en) 2003-11-18 2005-06-02 University Of Massachusetts Estradiol-related compounds and methods of use as anti-tumor agents
CN1930181A (zh) * 2004-01-07 2007-03-14 恩多研究公司 螺旋12定向的甾族药品
CA2564953A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
EP1756101A2 (en) * 2004-05-17 2007-02-28 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
DK2289872T3 (da) 2004-06-07 2017-10-09 Univ Tennessee Res Found Medicinsk anvendelse af en selektiv androgen receptor-modulator
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2008124922A1 (en) 2008-10-23
HUE027508T2 (en) 2016-10-28
CA2683522A1 (en) 2008-10-23
NZ580328A (en) 2012-05-25
US20090042844A1 (en) 2009-02-12
AU2008238559A1 (en) 2008-10-23
EP2147014A1 (en) 2010-01-27
EP2147014A4 (en) 2012-11-07
CA2683522C (en) 2013-01-22
US9284345B2 (en) 2016-03-15
AU2008238559B2 (en) 2012-05-31
EP2147014B1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
EP2147014B1 (en) 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
CN101243052B (zh) 螺旋结构12定位的非甾族抗雄激素物质
JP5795312B2 (ja) 17−ヒドロキシ−17−ペンタフルオロエチル−エストラ−4,9(10)−ジエン−11−アリール誘導体、その製造方法、その誘導体を利用した諸疾患の治療
JP5865845B2 (ja) プロゲステロン受容体アンタゴニスト
IE902457A1 (en) Androgen derivatives for use in the inhibition of sex¹steroid activity
JPH07501528A (ja) 性ステロイド活性阻害剤
EP0367576A2 (en) Estrogen nucleus derivatives for use in the inhibition of sex steroid activity
KR20160042873A (ko) 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체
AU2014366802A1 (en) Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN105518016B (zh) 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
SK139194A3 (en) The improved antiandrogens
ES2539121T3 (es) Derivados 19-nor-esteroides con un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado, su uso, así como medicamentos que contienen estos derivados
JP2002517482A (ja) 抗エストロゲン、その製造方法及びその製薬的使用
ES2397970T3 (es) Derivado de 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su utilización y medicamentos que contienen el derivado
ES2397972T3 (es) Derivado de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamento que contiene al derivado
AU2002210470B2 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
SK882003A3 (en) 16alpha-substituted steroid compounds, pharmaceutical composition comprising same and their use
KR20100102688A (ko) 17-히드록시-19-노르-21-카르복실산-스테로이드 γ-락톤 유도체, 그의 용도, 및 그 유도체를 함유하는 약제
WO2004089971A1 (en) Topical antiandrogenic steroids
TW200940562A (en) 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative, use thereof and medicinal products containing the derivative
TW201026718A (en) Use of 17β-cyano-19-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-19-androst-4-ene derivatives for parenteral administration